William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...

BTIG analyst Julian Harrison reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $4.00. The ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...

Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics ...

Nektar Therapeutics today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.

Nektar Therapeutics’s NKTR share price has surged by 22.00%, which has investors questioning if this is right time to sell.

SAN FRANCISCO and NEW YORK - Nektar Therapeutics (NASDAQ: NASDAQ:NKTR), a clinical-stage biotechnology company currently trading at $0.93 per share with a market capitalization of $173 million ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...